SG Americas Securities LLC Has $23.38 Million Stock Position in STERIS plc $STE

SG Americas Securities LLC lowered its holdings in shares of STERIS plc (NYSE:STE) by 32.7% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 105,707 shares of the medical equipment provider’s stock after selling 51,428 shares during the period. SG Americas Securities LLC’s holdings in STERIS were worth $23,375,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of STE. Board of the Pension Protection Fund bought a new stake in shares of STERIS in the fourth quarter worth $25,000. Harbor Investment Advisory LLC raised its position in STERIS by 115.4% during the 4th quarter. Harbor Investment Advisory LLC now owns 112 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 60 shares during the last quarter. Activest Wealth Management raised its position in STERIS by 423.8% during the 4th quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 89 shares during the last quarter. Measured Wealth Private Client Group LLC acquired a new position in STERIS during the 4th quarter worth about $28,000. Finally, Geneos Wealth Management Inc. lifted its holdings in STERIS by 416.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 104 shares during the period. Institutional investors and hedge funds own 94.69% of the company’s stock.

STERIS Stock Performance

Shares of STE opened at $206.68 on Thursday. The company has a current ratio of 2.09, a quick ratio of 1.54 and a debt-to-equity ratio of 0.25. The firm’s fifty day simple moving average is $213.19 and its two-hundred day simple moving average is $233.79. STERIS plc has a 12 month low of $195.14 and a 12 month high of $269.44. The stock has a market capitalization of $20.14 billion, a P/E ratio of 26.06 and a beta of 0.93.

STERIS (NYSE:STE) last announced its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing the consensus estimate of $2.86 by ($0.03). The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.59 billion. STERIS had a return on equity of 14.15% and a net margin of 13.18%.The business’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period last year, the business earned $2.74 EPS. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. As a group, analysts predict that STERIS plc will post 11.18 EPS for the current year.

STERIS Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 8th will be issued a dividend of $0.63 per share. The ex-dividend date is Monday, June 8th. This represents a $2.52 annualized dividend and a yield of 1.2%. STERIS’s dividend payout ratio is presently 31.78%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Weiss Ratings cut STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 27th. Piper Sandler reaffirmed an “overweight” rating and issued a $270.00 price objective on shares of STERIS in a research note on Thursday, May 21st. KeyCorp reduced their target price on STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Finally, Wall Street Zen downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 6th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $278.00.

Insider Activity

In other STERIS news, VP John Adam Zangerle sold 1,419 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $209.28, for a total transaction of $296,968.32. Following the completion of the sale, the vice president directly owned 35,259 shares of the company’s stock, valued at approximately $7,379,003.52. The trade was a 3.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel A. Carestio sold 3,054 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $214.64, for a total value of $655,510.56. Following the sale, the chief executive officer owned 65,021 shares of the company’s stock, valued at $13,956,107.44. This trade represents a 4.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 7,328 shares of company stock worth $1,554,051 over the last three months. 1.12% of the stock is currently owned by insiders.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.